Introduction
Epilepsy is a potentially life-threatening condition, 1 and there is evidence of a higher prevalence and incidence in Latin America 2 when compared with developed countries. Mortality in patients with epilepsy is known to be considerably higher than in the general population. [3] [4] [5] [6] [7] [8] [9] [10] [11] Unfortunately, mortality data from developing countries has been difficult to obtain because incidence studies are difficult to perform, death certificates are not very reliable, autopsies are not easy to obtain, and the cause of death is not usually known with certainty. [12] [13] [14] Ideally, identification of at risk individuals is imperative so that strategies to prevent mortality can be implemented. Furthermore, comparison of epilepsy mortality data between countries could potentially identify conditions that require specific regional treatment or medical attention.
To examine if epilepsy increases the risk of dying in Latin America, we reviewed cohort studies from this region that assessed mortality in populations with epilepsy compared with that expected in the general population.
Methods

Eligibility criteria
Type of studies: cohort studies of epilepsy cases from Latin America, evaluating mortality. Latin America includes Central America, South America, Mexico, and the Caribbean. No language or publication date restrictions were imposed.
Type of population: cohorts of any age collected in a community, neurology department, or epilepsy center were included.
Type of exposure: cohorts were selected if epilepsy was defined in accordance with International League Against Epilepsy definitions and recommendations.
Primary outcome measures: presentation of the observed number of deaths in people with epilepsy or of a calculated standardized mortality ratio (SMR).
Secondary outcome measures: distribution of causes of death.
Purpose: To assess the mortality related to epilepsy in Latin America. Methods: We searched MEDLINE, EMBASE, and LILACS from inception to December 2013 for articles evaluating mortality in patients with epilepsy in Latin America. Studies were included if they evaluated any mortality outcome, included a population of subjects with recurrent seizures or epilepsy, and contained original data analysis.
Results: The search strategy yielded 177 publications in MEDLINE and EMBASE, and 59 publications in LILACS; of which 18 met inclusion criteria for our overall review of epilepsy and mortality in Latin America. Most excluded studies did not report the mortality or lacked original data. We also included two references obtained from 2 non-systematic reviews fulfilling our inclusion criteria, and able to provide data for our analyses. Five studies reported Standardized Mortality Ratio (SMR), and demonstrated that people with epilepsy had a higher risk of death than the general population. The SMRs reported in two community-based studies were 1.34 and 2.45.
Conclusion:
The information about mortality in epilepsy in Latin America is very scarce. Comparisons cannot be made among studies due to methodological differences. More studies are needed. ß 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Information sources: studies were identified by searching electronic databases and scanning reference lists of articles. This search was applied to MEDLINE (1946-present) , EMBASE (1974-present) and LILACS (1981-present) . LILACS is the most important and comprehensive index of scientific and technical literature of Latin America and the Caribbean. The last search was run in December of 2013 (see Appendix A for full electronic search strategy for each database).
Study selection: two reviewers performed eligibility assessments independently. Any disagreement between the reviewers was resolved by consensus. Studies were included if they met the following criteria: (a) prospective or retrospective cohorts of subjects with the diagnosis of epilepsy, (b) presentation of a calculated standardized mortality ratio (SMR) or mortality rate (MR), and (c) contained original data analysis. We excluded studies evaluating mortality rates from epilepsy in the general population obtained from death certificates, non-systematic reviews (with the exception of using them to retrieve references not found in the above mentioned databases), and duplicate publications.
Data collection process: one review author extracted the following data from included studies and the second author verified the extracted data: country, year of study start, cohort type (prospective or retrospective), selected cases (incident or prevalent), source of cases (neurology department, epilepsy center, rural community or urban community), study size, proportion of treated people, age at study entry, years of follow-up, number of observed deaths, SMR, causes of death.
Results
The search strategy yielded 192 publications in MEDLINE, 425 publications in EMBASE, and 415 publications in LILACS. After the first screening, 14 documents were read and critically reviewed. Five final articles were selected ( Fig. 1 ).
Description of studies
Five references from five different countries were identified. Two studies were community based 15, 16 one rural and the other urban. Both were retrospective studies and prevalent cases were selected (Table 1) . Interestingly, almost 45% of the patients in these two studies saw remission of their epilepsy during the 8-10 years of the follow-up even though, apparently, only 12% of the patients had taken antiepileptic medications for more than one year. 15 Three articles corresponded to selected populations with epilepsy. All three were hospital-based, 12, 17, 18 and in one of them the data was obtained from an epilepsy center. 18 All three had a prospective design, although only one selected incident cases. 12 Additionally, two of these articles were focused on young populations 17, 18 (Table 1) .
All causes of mortality
There were two community-based studies ( Table 2 ). In the urban community-based study in Argentina, the SMR was 2.45 and the MR 17.86, while in the rural-community-based study in Bolivia the SMR was 1.34 and the MR was 9.71. Age-specific SMRs were available for the study done in Ecuador; while MRs were available in the study done in Bolivia (Table 3 ). In regards to etiology, only one study evaluated the mortality in patients with idiopathic epilepsy and did not find a significantly increased risk of death (Table 4) , however patients with remote symptomatic epilepsy did have an increased risk. In this last group of patients with symptomatic epilepsy, 61% of cases at risk had neurocysticercosis (NCC)-related epilepsy, and were living in rural areas. 15 Furthermore, the single urban community-based study showed a MR of 40 per 1000 patient-year in the symptomatic epilepsy group, in whom 50% had tumor-related epilepsy. 16 
Cause-specific mortality
The most common cause of death in community based studies corresponded to underlying disease-related deaths or epilepsyunrelated deaths (Table 5) , although almost 25% of deaths had unknown cause. In selected population-based studies, 20-42% of the observed deaths were in relation with SUDEP, although only 7-14% of them were determined to be definitive cases. 
Discussion
Mortality can be divided into deaths attributable to epilepsy (epilepsy related), deaths from the pathology responsible for the epilepsy, and deaths from unrelated conditions. 19 Deaths due to sudden unexpected death in epilepsy (SUDEP), status epilepticus (SE), suicide, and accidents are considered to be epilepsy-related. 20 Mortality in patients with epilepsy can be an indirect estimator of the epilepsy severity and its public health impact.
10 Different measures to estimate mortality have been used. Case fatality refers to the number of deaths divided by the number of patients with the disease in the study population. It is influenced by the distribution of prognostic factors and by differences in medical care. The mortality rate (MR) is the number of deaths that occur in a defined population, in a specific time, divided by the person-years at risk in that population. It is influenced by the incidence of epilepsy in a population, the case fatality, and the age distribution of the population. The standardized mortality ratio (SMR) is the ratio of the observed number of deaths in a population with epilepsy in comparison to the mortality rate in the general population, adjusted by age and sex specific. Even though it may be difficult to compare SMRs between studies because the measure depends on the mortality rate in the reference population, 19 the use of SMRs is considered to the best measure to report mortality. Population-based cohorts assessing incident cases represent the gold standard for studies on mortality. These cohorts allow for an adequate and complete collection of data as well as the observation throughout the patients' lifespans. 10 We did not find this type of cohort in our review, even though the studies of Nicolleti et al. and Kochene et al. are very useful, considering that are based in cohorts and report SMRs. Even though these 2 studies had a different methodology, and comparison of SMRs has to be done with caution, they demonstrated SMRs ranging from 1.34 to 2.45, and are relevant because they included patients from the general population and probably a full spectrum of patients with epilepsy (e.g. intractable and not intractable cases). The rates reported in these studies are comparable to studies where specific populations have been assessed such as the study in Rochester, Minnesota. 3 Limitations related to the use of cohorts for assessing prevalence and the small number of cases in these studies should be taken into account. Prevalence cohorts might underestimate short-term mortality because the more serious cases die in the early phase of the disease and are not included in the calculation of deaths over the period of observation. 10 Also, the median age of the subjects included in the studies was not available, which would allow us to have a better sense on the degree of heterogeneneity in these cohorts. Two hospital-based studies reported SMRs of 3.21 and 6.3, which are higher than the rates reported by Nicolette and Kochen. 15, 16 These kinds of studies are more likely to include severe cases with respect to seizure frequency, duration of epilepsy, and resistance to antiepileptic drug therapy than might affect the results. Mortality rates based on death certificates in the general population ranged from 0.9 to 4.6/100 000 person-year with a potential temporal trend to decline. Based on a single underlying cause of death listed on the death certificate, such tabulations underestimate the number of deaths among people with epilepsy. In addition, the presence of epilepsy is not necessarily recorded accurately in death certificates, and even when recorded, the accuracy of a diagnosis included on a death certificates has been questioned. 21 More epidemiological studies exploring MR are required to support any trends. SUDEP is probably the most common direct epilepsy-related cause of death. 14 Nashef has proposed the following definition:
Sudden, unexpected, witnessed or unwitnessed, non-traumatic and non-drowning deaths in patients with epilepsy, with or without evidence of a seizure and excluding documented status epilepticus, in which post-mortem examination does not reveal a toxicologic or anatomic cause of death. 22 that SUDEP cases in children are related to chronic uncontrolled epilepsy. Improved seizure control by treatment (pharmacological or surgical) would seem to be one of the most important measures to prevent SUDEP. Status epilepticus (SE) is common in patients admitted to hospitals in resource poor countries. Most studies on SE in these countries describe convulsive status epilepticus (CSE), since nonconvulsive epilepticus is rarely detected in these regions, due to the lack of resources (continuous EEG monitoring). 25 Most CSE have a known etiology (symptomatic), with the increased incidence attributed to the increased incidence of infections. Many hospitals in these countries, particularly those in rural areas have few drugs to treat CSE, and many hospitals do not have intensive care facilities such as ventilators or sufficient health personnel to provide optimal management. Hence, strong considerations should be given to the training of health care providers as well as the provision of necessary equipment so that they are able to initiate therapies for CSE. Despite the methodological difficulty comparing studies, it seems that mortality in people with epilepsy in Latin America is similar to the that reported in developed countries. 8 Few studies have been published and it is possible that studies from very poor countries in Latin America could report higher rates. The lack of standardized treatment programs, the economic problems than might not guarantee the drug supply, the poor healthcare infrastructure, and the distance difficulties of rural population, may increase the mortality, but in the very few studies that have reported, that is not seen. Only one study evaluated the mortality in patients with idiopathic epilepsy and did not find a significant increased risk of death. 15 Meanwhile, most deaths in the other studies corresponded to symptomatic cases. The information about risk factors for death has not been explored in Latin American studies. This information needs more scrutiny in the future in order to establish preventive measures. Despite the main limitation of this study, which is the limited data found in the literature, the studies reported in this review provide interesting information about rates of mortality in Latin America. Also, one has to be cautious interpreting the different SMRs, because of the different methodologies used in the studies included in this review. But, these studies reported SMRs indicating that epilepsy has a higher risk of death than the general population, but not higher than that reported in developed countries. The SMRs reported in hospital-based studies were higher than those in community based studies probably owing to a pattern of referral of more complex cases with intractable epilepsy and a higher risk of death. Overall, few studies have been published regarding mortality in Latin America. Interesting questions such as a higher mortality rate of patients with epilepsy in Latin America compared with other continents or regions cannot be supported with the reported studies. The mortality reported in patients with status epilepticus is similar to series of cases from other regions of the world. More studies exploring specific causes of mortality are needed as very little information has been published regarding SUDEP and other causes of mortality in patients with epilepsy. 
